Literature DB >> 16736418

SAA1 alpha/alpha alleles in amyloidosis.

Engin Kelkitli1, Birsen Bilgici, Bülent Tokgöz, Melda Dilek, Abdülkerim Bedir, Ilkser Akpolat, Cengiz Utas, Tekin Akpolat.   

Abstract

BACKGROUND: Amyloidosis, mainly AA type, is one of the common diseases in nephrology clinics in Turkey. AA type amyloidosis is a complication of various chronic infections or inflammatory diseases such as familial Mediterranean fever (FMF), rheumatoid arthritis (RA), tuberculosis and bronchiectasis. A controversy exists in the literature regarding the relationship between SAA1 genotypes and AA type amyloidosis. This study aimed to investigate SAA1 gene polymorphism in different patient groups: 1) amyloidosis, 2) FMF and 3) healthy controls.
METHODS: Eighty-two patients from the three groups were included in the study: 1) amyloidosis, 2) FMF without amyloidosis, and 3) healthy controls. SAA1 genotypes were studied by the polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP) method.
RESULTS: The homozygous alpha/alpha genotype is the most common SAA1 genotype among patient groups with amyloidosis, and the alpha/alpha genotype frequency is significantly higher than in healthy controls (68 vs. 38%, p<0.05).
CONCLUSIONS: The SAA1 alpha/alpha genotype is a risk factor for AA type amyloidosis in Caucasoid populations and more studies are needed to investigate why the gamma/gamma genotype is associated with AA type amyloidosis in Japan.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736418

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  2 in total

1.  [Amyloidoses in the Berlin Museum of Medical History of the Charité].

Authors:  C Röcken; N Widulin; T Schnalke
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

2.  SAA1 alpha/alpha alleles in Behçet's disease related amyloidosis.

Authors:  Umut Utku; Melda Dilek; Ilkser Akpolat; Abdülkerim Bedir; Tekin Akpolat
Journal:  Clin Rheumatol       Date:  2006-10-13       Impact factor: 3.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.